Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Fate Therapeutics stock | $58.16

Learn how to easily invest in Fate Therapeutics stock.

Fate Therapeutics Inc is a biotechnology business based in the US. Fate Therapeutics shares (FATE) are listed on the NASDAQ and all prices are listed in US Dollars. Fate Therapeutics employs 356 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Fate Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – FATE – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Fate Therapeutics stock price (NASDAQ: FATE)

Use our graph to track the performance of FATE stocks over time.

Fate Therapeutics shares at a glance

Information last updated 2021-10-24.
Latest market close$58.16
52-week range$42.64 - $121.16
50-day moving average $62.89
200-day moving average $77.08
Wall St. target price$108.79
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.34

Buy Fate Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Fate Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Fate Therapeutics price performance over time

Historical closes compared with the close of $58.16 from 2021-10-25

1 week (2021-10-20) -2.37%
1 month (2021-09-27) -9.63%
3 months (2021-07-27) -27.43%
6 months (2021-04-27) -37.14%
1 year (2020-10-26) 24.01%
2 years (2019-10-25) 287.48%
3 years (2018-10-26) 333.06%
5 years (2016-10-26) 2,484.89%

Fate Therapeutics financials

Revenue TTM $48 million
Gross profit TTM $-94,189,000
Return on assets TTM -11.82%
Return on equity TTM -34.58%
Profit margin 0%
Book value $7.98
Market capitalisation $5.6 billion

TTM: trailing 12 months

Shorting Fate Therapeutics shares

There are currently 11.4 million Fate Therapeutics shares held short by investors – that's known as Fate Therapeutics's "short interest". This figure is 3.4% down from 11.8 million last month.

There are a few different ways that this level of interest in shorting Fate Therapeutics shares can be evaluated.

Fate Therapeutics's "short interest ratio" (SIR)

Fate Therapeutics's "short interest ratio" (SIR) is the quantity of Fate Therapeutics shares currently shorted divided by the average quantity of Fate Therapeutics shares traded daily (recently around 951331.80300501). Fate Therapeutics's SIR currently stands at 11.98. In other words for every 100,000 Fate Therapeutics shares traded daily on the market, roughly 11980 shares are currently held short.

However Fate Therapeutics's short interest can also be evaluated against the total number of Fate Therapeutics shares, or, against the total number of tradable Fate Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Fate Therapeutics's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Fate Therapeutics shares in existence, roughly 120 shares are currently held short) or 0.1675% of the tradable shares (for every 100,000 tradable Fate Therapeutics shares, roughly 168 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Fate Therapeutics.

Find out more about how you can short Fate Therapeutics stock.

Fate Therapeutics share dividends

We're not expecting Fate Therapeutics to pay a dividend over the next 12 months.

Fate Therapeutics share price volatility

Over the last 12 months, Fate Therapeutics's shares have ranged in value from as little as $42.64 up to $121.16. A popular way to gauge a stock's volatility is its "beta".

FATE.US volatility(beta: 1.73)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fate Therapeutics's is 1.7291. This would suggest that Fate Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Fate Therapeutics overview

Fate Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors, as well as ProTmune for the treatment of hematologic malignancies and rare genetic disorders. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc.

Frequently asked questions

What percentage of Fate Therapeutics is owned by insiders or institutions?
Currently 1.754% of Fate Therapeutics shares are held by insiders and 104.174% by institutions.
How many people work for Fate Therapeutics?
Latest data suggests 356 work at Fate Therapeutics.
When does the fiscal year end for Fate Therapeutics?
Fate Therapeutics's fiscal year ends in December.
Where is Fate Therapeutics based?
Fate Therapeutics's address is: 3535 General Atomics Court, San Diego, CA, United States, 92121
What is Fate Therapeutics's ISIN number?
Fate Therapeutics's international securities identification number is: US31189P1021
What is Fate Therapeutics's CUSIP number?
Fate Therapeutics's Committee on Uniform Securities Identification Procedures number is: 31189P102

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site